Pan et al. Supplemental Data Supplemental Figure 1. ITPKB expression positively associated with cisplatin resistance in cancer cell lines and primary cancer patient samples. (A) Schematic view of RNAi screen. (B) The mRNA and protein level of ITPKB in a panel of cancer cell lines. (C) ITPKB expression levels in head and neck, lung, and ovarian cancer patient-derived xenograft (PDX) tumors. (D) Representative images of scores 0, 1, 2, 3 for ITPKB immunohistochemistry (IHC) staining using primary tumor specimens collected from head and neck squamous cell carcinoma (HNSCC) patients treated with platinum therapy are shown. (E) Representative ITPKB IHC images of tumors from HNSCC patient groups who showed response (top) or no response (bottom) to platinum therapy within a two-year duration are shown. Scale bars represent 100 µm. Data are mean ± SD of three technical replicates (B top) and are representative two (B, C) independent biological experiments. Supplemental Figure 2. Knockdown or knockout of ITPKB attenuates cisplatin-resistant cancer cell proliferation. (A) Representative images of colony formation assays using ITPKB knockdown cells are shown. (B) Cell viability (top) and colony formation potential (bottom) of KB-3-1 cisR , A549 cisR , and A2780 cisR cells with ITPKB knockout in the presence or absence of cisplatin. Cells were transduced with ITPKB sgRNA clones and treated with sub-lethal doses of cisplatin (KB-3-1 cisR and A2780 cisR 5 µg/ml, A549 cisR : 2 µg/ml) for 48 hr for cell viability. ITPKB knockout efficiency was assessed by immunoblotting. (C) Representative images of colony formation assays using ITPKB knockout cells are shown. (D) Proliferation rates of KB-3-1 cisR xenograft tumors from Figure 2C were assessed by Ki-67 staining. Scale bars represent 50 µm for Ki-67 staining. Data are mean ± SD from three technical replicates of each sample and are representative of three (B; top) and one (B; middle) independent biological experiments. Statistical analysis was performed by 1-way ANOVA (ns: not significant; ****P < 0.0001).
Supplemental Figure 3. Knockdown of ITPKB and cisplatin treatment neither affect bioenergetics and anabolic biosynthesis nor attenuate activity of AKT and MEK. (A and B)
Effect of ITPKB knockdown and cisplatin treatment on bioenergetics (A), RNA and lipid biosynthesis (B) . Cells were treated with sub-lethal doses of cisplatin (KB-3-1 cisR : 5 µg/ml, A549 cisR : 2 µg/ml). ATP levels and glycolytic rates were measured to profile bioenergetics. RNA and lipid synthesis levels were determined by measuring 14 C incorporation in RNA or lipid from 14 C-glucose in cells. (C and D) Effect of targeting ITPKB on cisplatin uptake (C) and cisplatininduced DNA damage (D) in cells with ITPKB knockdown and cisplatin treatment as in (A), were quantified using specific antibodies against cisplatin-DNA adducts and phospho-gH2AX, respectively. (E) Targeting ITPKB activates AKT but not MEK, and cisplatin treatment together with ITPKB knockdown does not further alter the AKT or MAPK pathway. Cells were treated with cisplatin as in (A) and activation of the AKT pathway was examined by assessing phosphorylation levels of AKT (T308) and S6 (S240/S244). Activation of MAPK pathway was assessed by phospho-MEK (S221) and phospho-ERK1/2(T202/Y204). Data are mean ± SD from three technical replicates of each sample and are representative of two independent biological experiments. Statistical analysis was performed by 1-way ANOVA (ns: not significant).
Supplemental Figure 4. ITPKB contributes to cisplatin-resistant cell survival by controlling cytosolic ROS but not mitochondrial ROS. (A)
Effect of ITPKB knockdown and extracellular IP4 on cisplatin-induced mitochondrial ROS. Cells were incubated with 1 µM IP4-PM and sublethal doses of cisplatin ((KB-3-1 cisR : 5 µg/ml, A549 cisR : 2 µg/ml). Mitochondrial superoxide and mitochondrial H2O2 were determined using mitoSOX and mitoPY1, respectively. (B-C) Effect of mito-TEMPO (B) or catalase overexpression (C) on ROS, apoptosis, and cell viability in cells with ITPKB knockdown and cisplatin treatment. 10 µM of mito-TEMPO or myc tagged catalase were introduced in cisplatin treated cells as in (A). Apoptotic cell death and cell viability were assessed by annexin V staining and CellTiter-Glo Luminescent Viability Assay. (D) Representative images of Ki-67 IHC staining in harvested tumors from each group of KB-3-1 cisR xenograft mice from Figure 5D are shown. Scale bars represent 50 µm. Data are mean ± SD from three technical replicates of each sample and are representative of three independent biological experiments. Statistical analysis was performed by 1-way ANOVA (ns: not significant; **P < 0.01; ***P < 0.005; ****P < 0.0001).
Supplemental Figure 5. ITPKB confers resistance to DNA damaging agents by inhibiting NOX4 activity in cancer cells. (A)
Effect of ITPKB knockout on NOX activity, ROS level, and apoptosis in the presence and absence of cisplatin. (B) Effect of NOX inhibitor GKT137831 on ROS level, NOX activity, and cell viability in ITPKB knockdown cells in the presence of paclitaxel or DNA damaging agents. KB-3-1 cisR cells were treated with sublethal doses of chemotherapy agents (5 µg/ml cisplatin, 0.2 µM doxorubicin, 2 µM mitomycin C, 1 nM paclitaxel) and GKT137831 (10 µM). ROS/NOX activity and cell viability were determined after 12 hr and 48 hr, respectively. (C) Effect of NOX1 knockdown on ROS level, NOX activity, and cell viability in ITPKB knockdown cells in the presence of cisplatin. Data are mean ± SD from three technical replicates of each sample and are representative of two independent biological experiments. Statistical analysis was performed by 1-way ANOVA (ns: not significant; *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.0001). Comparison of ITPKB staining intensity between HNSCC patient groups who showed response or no response to platinum therapy within a twoyear duration. Tumors were collected before or after platinum therapy. Response: patients who responded to platinum therapy for a duration of two years; No response: patients who lost response within the two-year period and had regrowth of tumors off treatment. Data are mean ± SD from n=5 for 'Response' group and n=8 for 'No response' group. Statistical analysis was performed by paired two-tailed Student's t test for (A) and non-paired two-tailed Student's t test for (C) (*P < 0.05; ***P < 0.005).
Supplemental

Supplemental Figure 9. BAMB-4 sensitizes cells to cisplatin by inhibiting ITPKB not IPMK. (A)
Effect of BAMB-4 on ROS level and NOX activity in cisplatin treated cells with or without ITPKB knockdown. Cells were treated with cisplatin (KB-3-1 cisR : 5 µg/ml, A549 cisR : 2 µg/ml) and BAMB-4 (10 µM) for 12 hr and ROS and NOX activity were examined. (B) Effect of BAMB-4 on cisplatin IC50 in cells with or without ITPKB. (C) Effect of BAMB-4 on IPMK activity. GST-IPMK was enriched from cells by GST-pull down and IPMK activity was assessed by ADP-Glo kinase assay using IP3 as a substrate. (D) In vitro IPMK activity was measured in the presence of increasing concentrations of BAMB-4. (E) Effect of BAMB-4 on cisplatin response in cells with or without IPMK knockdown. Cells were treated with cisplatin (KB-3-1 cisR and A2780 cisR : 5 µg/ml, A549 cisR : 2 µg/ml) and BAMB-4 (10 µM) for 48 hr and cisplatin IC50 was measured. Data are mean ± SD from three technical replicates and are representative of two independent biological experiments. Statistical analysis was performed by 1-way ANOVA (ns: not significant; ***P < 0.005; ****P < 0.0001).
Supplemental Figure 10. BAMB-4 and cisplatin induced no significant toxicity or kidney injury in mice. (A)
Histology of hematoxylin and eosin (H&E) stained tissues of representative mice in vehicle control, cisplatin, BAMB-4, and combination treated groups. Athymic nude mice (lung cancer PDX) and NOD scid gamma mice (ovarian cancer PDX) were treated with 5 mg/kg of cisplatin and 10 mg/kg of BAMB-4 intraperitoneally twice a week for 38 days in nude mice and 16 days in NSG mice. Scale bars in (A) represent 50 µm. (B-G) Nephrotoxicity was assessed by measuring body weight (B) and quantification of kidney injury biomarkers including Scr (C), Bun (D), NAG activity (E), proteinuria (F), and kim-1 staining (G). 5 mg/kg of cisplatin and 10 mg/kg of BAMB-4 intraperitoneally twice a week for 21 days in nude mice for (B)-(G). Positive control group for kim-1 staining was administered 10 mg/kg/day of cisplatin for 3 consecutive days (n=7/group). Scale bars in (G) represent 100 µm. Data are mean ± SD from 7 mice/group. Statistical analysis was performed by 2-way ANOVA (ns: not significant).
